ZNF711

Across TCGA pan-cancer cohorts, ZNF711 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZNF711 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ZNF711 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF711 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM and LSCC are the cancer types where ZNF711 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.671	0.446	.019	9	view →
LSCC	DFS	Median	All	0.432	0.944	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ZNF711–GBM (DFS)

Open the GBM breakdown →